In agreement with this, in mice pre‐treated with CM the (α‐catenin silenced‐HCCLM3 cells)‐induced bone microenvironment accelerated HCCLM3 cells BM; as shown by early and increased systemic bone metastatic onsets and larger bone metastatic tumor‐burden, higher serum LGALS3 level, and severe osteolytic skeletal complications; as indicated by larger osteolytic area, lower systemic BMD, and increased TRAP+‐osteoclasts (Figure 5B–E). Here, LGALS3 is linked to neoplasm.